Cannabidiol: Promise and Pitfalls

Epilepsy Currents

Volumn 14, Issue 5, 2014, Pages 250-252

  Welty, Timothy E ^a   Luebke, Adrienne ^b   Gidal, Barry E ^b  

^a DRAKE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL;

ANTICONVULSANT ACTIVITY; CALCIUM HOMEOSTASIS; CANNABIS USE; DRUG INTERACTION; DRUG MECHANISM; DRUG TOLERABILITY; EPILEPSY; EPILEPTOGENESIS; HUMAN; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYNAPSE; SYSTEMATIC REVIEW (TOPIC);

EID: 84908394165     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7597-14.5.250     Document Type: Review

References (17)

1. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802.
2. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ. Cannabidiol displays antiepileptiform and anti-seizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010;332:569- 577.
3. Falenski KW, Carter DS, Harrison AJ, Martin BR, Blair RE, DeLorenzo RJ. Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res 2009;1262:64-72.
4. Hofmann ME, Frazier CJ. Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved therapeutic intervention. Exp Neurol 2013;244:43-50.
5. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol, and D9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
6. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479-1494.
7. Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 2012;133:79-97.
8. Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, Burnett MD, Yamasaki Y, Stephens GJ, Whalley BJ, Williams CM. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012;21:344-352.
9. Brust JCM, Ng SKC, Hauser AW, Susser M. Marijuana use and the risk of new onset seizures. Trans Am Clin Climatol Assoc 1992;103:176-181.
10. Gross DW, Hamm J, Ashworth NL, Quigley D. Marijuana use and epilepsy. Neurology 2004;62:2095-2097.
11. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2012;6:CD009270.
12. Trembly B, Sherman M. Double-Blind Clinical Study of Cannabidiol as a Secondary Anticonvulsant. Proceedings of the Marijuana '90 International Conference on Cannabis and Cannabinoids, Kolympari, Crete, July 1990. Cologne, Germany: International Association for Cannabinoid Medicines, 1990:5.
13. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1985;69:14.
14. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175-185.
15. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften 1978;65:174-179.
16. Zhornitsky S, Potvin S. Cannabidiol in humans-The quest for therapeutic targets. Pharmaceuticals 2012;5:529-552.
17. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, Woodcock H, Dorward P, Pigliacampo B, Close S, Platt B, Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavior. Psychopharmacology (Berl) 2012;219:859-873.